MARKET

AGEN

AGEN

Agenus
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.395
-0.265
-7.24%
After Hours: 3.420 +0.025 +0.74% 17:10 03/03 EST
OPEN
3.630
PREV CLOSE
3.660
HIGH
3.685
LOW
3.390
VOLUME
3.55M
TURNOVER
--
52 WEEK HIGH
5.95
52 WEEK LOW
1.820
MARKET CAP
645.56M
P/E (TTM)
-3.1204
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2020 Financial Report
Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced it will release its fourth quarte...
GlobeNewswire · 1d ago
Best Penny Stocks To Buy Before Friday? 4 Under $4 To Watch
Feb 24, 2021 (Penny Stocks via COMTEX) -- 4 Penny Stocks To Watch With Increased Volume This Month Penny stocks were in direct focus on Wednesday. Partially...
Penny Stocks · 02/24 21:10
Seeking Alpha Catalyst Watch
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a
Seekingalpha · 02/19 20:15
Agenus names new chief commercial officer
Agenus (AGEN) appoints of Andy Hurley as its chief commercial officer.Andy brings three decades of international experience as a strategic commercial leader at large and small biopharmaceutical companies.He joins Agenus from his most
Seekingalpha · 02/09 22:21
Agenus Says Andy Hurley Named Chief Commercial Officer >AGEN
Agenus Says Andy Hurley Named Chief Commercial Officer >AGEN
Dow Jones · 02/09 22:07
Press Release: Andy Hurley Named Agenus Chief Commercial Officer
Dow Jones · 02/09 22:06
--Agenus Names Andy Hurley Chief Commercial Officer
MT Newswires · 02/09 17:25
Analysts Are Bullish on These Healthcare Stocks: Agenus (AGEN), Entera Bio (ENTX)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Agenus (AGEN) and Entera Bio (ENTX) with bullish
SmarterAnalyst · 02/09 17:25
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AGEN. Analyze the recent business situations of Agenus through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AGEN stock price target is 8.00 with a high estimate of 8.00 and a low estimate of 8.00.
EPS
Institutional Holdings
Institutions: 206
Institutional Holdings: 108.77M
% Owned: 57.20%
Shares Outstanding: 190.15M
TypeInstitutionsShares
Increased
48
12.00M
New
28
-918.15K
Decreased
37
6.40M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-3.96%
Pharmaceuticals & Medical Research
-1.89%
Key Executives
Chairman/Chief Executive Officer/Co-Founder/Director
Garo Armen
President/Chief Operating Officer
Jennifer Buell
Chief Accounting Officer/Vice President - Finance
Christine Klaskin
Chief Compliance Officer/Vice President/General Counsel/Secretary
Evan Kearns
Vice President
Don Vidic
Vice President
Donald Vidic
Other
Andy Hurley
Lead Director/Independent Director
Timothy Wright
Director
Paul Clark
Director
Susan Hirsch
Independent Director
Brian Corvese
Independent Director
Allison Jeynes-Ellis
Independent Director
Wadih Jordan
Independent Director
Ulf Wiinberg
  • Dividends
  • Splits
  • Insider Activity
No Data
About AGEN
Agenus Inc. (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon). The Company's discovery pipeline includes a range of checkpoint modulating (CPM) antibodies. The Company's vaccine platforms include its heat shock protein (HSP)-based Prophage vaccine candidates, and its synthetic vaccine candidates, ASV and PSV.

Webull offers kinds of Agenus Inc stock information, including NASDAQ:AGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AGEN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AGEN stock methods without spending real money on the virtual paper trading platform.